紫杉醇+洛铂化疗方案治疗晚期卵巢癌的临床效果及安全性

Clinical effect and safety of paclitaxel+lobaplatin chemotherapy regimen in the treatment of advanced ovarian cancer

目的分析紫杉醇+洛铂化疗方案治疗晚期卵巢癌的临床效果及安全性。方法选取我院2019年1月至2020年12月收治的46例晚期卵巢癌患者为研究对象,以随机数字法将其分为常规组(23例,紫杉醇+顺铂化疗方案)与观察组(23例,紫杉醇+洛铂化疗方案),比较两组的治疗效果。结果观察组的治疗总有效率高于常规组,平均生存期长于常规组,肝肾功能异常发生率低于常规组(P<0.05)。治疗后,观察组的人附睾蛋白4(HE4)、糖类抗原125(CA125)水平均显著低于常规组,生活质量各维度评分均显著高于常规组(P<0.05)。结论相较于紫杉醇+顺铂化疗方案,紫杉醇+洛铂化疗方案治疗晚期卵巢癌的效果显著,值得临床应用。

Objective To analyze the clinical effect and safety of paclitaxel+lobaplatin chemotherapy regimen in the treatment of advanced ovarian cancer.Methods A total of 46 patients with advanced ovarian cancer admitted in our hospital from January 2019 to December 2020 were selected as the research objects.The patients were divided into conventional group(23 cases,paclitaxel+cisplatin chemotherapy regimen)and observation group(23 cases,paclitaxel+lobaplatin chemotherapy regimen)by random number method,and the treatment effects of the two groups were compared.Results The total effective rate of treatment of the observation group was higher than that of the conventional group,the average survival time was longer than that of the conventional group,and the incidence of abnormal liver and kidney function was lower than that of the conventional group(P<0.05).After treatment,the levels of human epididymis protein 4(HE4)and carbohydrate antigen 125(CA125)in the observation group were significantly lower than those in the conventional group,and the scores of all dimensions of quality of life were significantly higher than those in the conventional group(P<0.05).Conclusion Compared with paclitaxel+cisplatin chemotherapy regimen,paclitaxel+lobaplatin chemotherapy regimen in the treatment of advanced ovarian cancer has a significant effect,which is worthy of clinical application.